A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Latest Information Update: 08 May 2025
At a glance
- Drugs Capivasertib (Primary) ; Docetaxel (Primary) ; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms CAPItello-280
- Sponsors AstraZeneca
Most Recent Events
- 29 Apr 2025 Status changed from active, no longer recruiting to discontinued based on the recommendation of the Independent Data Monitoring Committee (IDMC) following their review of data from a pre-specified interim analysis.
- 27 Jan 2025 Planned End Date changed from 21 Dec 2026 to 4 Mar 2026.
- 27 Jan 2025 Planned primary completion date changed from 21 Dec 2026 to 4 Mar 2026.